A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
about
Patient education for adults with rheumatoid arthritisThomas John (Jock) Murray, OC, MD, FRCP(C), MACP, LLD(HON), DSc(Hon), FRCP(Lon): a conversation with the editor. Interview by William Clifford Roberts.Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysisReview of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agentsStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaWhere will the next generation of stroke treatments come from?Randomized clinical trials in stroke research.North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development GroupStroke: management and rehabilitation. Part III of III.Retinopathy in a population-based studyPreventing dementia.The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.Medical management of patients with an acute stroke: treatment and prevention.Aspirin for the prevention of vascular death in women.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesTIA and minor stroke. How to identify and treat patients at risk for recurrent cerebral ischemia.Management of extracranial carotid artery diseaseThe perilous state of independent randomized clinical trials and related applied research in Canada.Sex differences in stroke.Meta-analysis in the assessment of treatment outcome.Managing disability from stroke.Experience with barbiturate therapy for cerebral protection during carotid endarterectomyPrevention of recurrent ischemic stroke.Plasminogen activators and ischemic stroke: conditions for acute delivery.Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease.Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study.Adhesive interactions of platelets and their blockade.Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke.The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review.Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy.2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/AmericanFactors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.Nanotechnology for the detection and therapy of stroke.Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.Therapeutic progress--review XXXV. Aspirin in the next decade.
P2860
Q24248756-E534FD12-B9AD-4E51-A8CD-A827F131E905Q24533554-F4DEA705-E790-4405-A9ED-762CA3461311Q28076042-BEBBBF84-548D-4360-8DCE-A908FBB4363AQ28192470-A35615B5-1E4A-495B-92A5-1B0E846C0E07Q28677503-57A481FD-C4C4-4521-9DA7-D0AF070D0C3AQ28677657-359576A6-7BB4-4925-ACDB-60D0C261E222Q28742458-BAEF40F3-D6DB-4855-972D-66514EA8417BQ30979218-A36A3173-C336-456B-BB8F-D595E8C9962DQ33725049-3F018C08-1ACF-4BD7-97C5-5975E63BCA1CQ33789869-6F218BAB-4DF3-49CB-82E0-39AD32D45F8BQ34116128-74B7F46B-37EA-41AA-9EC5-5F8CA0B6E810Q34163862-AE6B1944-5275-4CCD-BE46-65F38DCFCAE7Q34174220-416833DC-5F29-497F-A2DE-DECB85D31F36Q34403671-6BC15406-BC43-434F-8323-EF785AC0FE45Q34519530-36F8BBCC-AB4D-49C3-B3DB-49310BFD73AFQ35610113-6236BDBA-62E6-4DCD-8F69-391035D0F804Q35657196-36728694-A19B-4295-B861-EE504CD5AFEEQ35752619-1A608EC9-1E57-4CE1-A94C-6B08B567E363Q36082349-19665CDC-4D44-475D-8558-BFB1D14A16C7Q36412642-748799EF-B7D1-41D2-B109-4DF51597F46FQ36458392-E3ACABB6-7D6A-489D-BC44-7697A53C9BF0Q36459100-06D22725-89CC-4BAB-A21A-7D91017F03E8Q36511692-B85B632B-AF92-4EFB-A6D2-B0C6CF3F01ACQ36576216-82F10BCF-2E3B-4A47-9A93-8AAADD062405Q36805634-7779F057-6EDE-40CD-837F-F80936A0D26EQ36819598-BF831256-4732-41C4-94AB-B2CBF5978ED9Q36988667-9CB93E14-37FE-423B-9FF0-2C4733071FEEQ37091738-242AC805-635F-438A-AF0C-2B1D28495847Q37424702-F15A708F-B6DF-48AF-8839-AE9B4AAA5E01Q37711758-49F31EB1-84B9-418A-A166-157CAAE43DC8Q37730309-AE5D3B09-3767-4C94-B17F-988093DE20DDQ37773416-C53EF1FA-58F7-4390-B3CE-0878EDB620BBQ37858846-F7850EE3-E802-4F1F-BF72-666F6AE16E04Q37876347-3F28A7B1-5A1E-42CB-A6E9-46F0672B4C52Q38051636-3153A032-25BC-4B82-B48E-939235877AAAQ38071039-B966728F-7EC4-4398-9AA0-04FD9F44EBBAQ38169038-52D2057A-5552-4E3D-932B-499DF431DCA8Q38201415-E699B007-6843-4CBB-B056-B0F454BE4FF9Q38688827-5379B50F-E630-4015-B766-8213FDB78A36Q38697534-3A7BD504-22CC-46C1-8A60-FAF6E639E05C
P2860
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
@en
type
label
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
@en
prefLabel
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
@en
P1476
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
@en
P2093
Canadian Cooperative Study Group
P356
10.1056/NEJM197807132990201
P407
P577
1978-07-01T00:00:00Z